专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010007074A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES 审中-公开
标题翻译：吡咯并[1,5-A]吡啶衍生物
公开(公告)号：WO2010007074A1
公开(公告)日：2010-01-21
申请号：PCT/EP2009/059013
申请日：2009-07-15
申请人： GLAXO GROUP LIMITED , HEER, Jag, Paul , NORTON, David , WARD, Simon, E
发明人： HEER, Jag, Paul , NORTON, David , WARD, Simon, E
IPC分类号： C07D487/04 , A61K31/519 , A61P25/04
CPC分类号： C07D487/04
摘要： The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial.
摘要翻译：本发明涉及新的哌嗪衍生物; 进行准备; 含有该衍生物的药物组合物; 以及在治疗中使用衍生物治疗阻断Cav2.2钙通道有益的疾病。

2. 发明申请

WO2009053448A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE 审中-公开
标题翻译：潜在的AMPA受体的化合物及其在医学中的应用
公开(公告)号：WO2009053448A1
公开(公告)日：2009-04-30
申请号：PCT/EP2008/064407
申请日：2008-10-24
申请人： GLAXO GROUP LIMITED , CHAN, Wai, Ngor , HARRISON, Stephen , HUGHES, Owen, Rhys , NEESOM, James, Kenneth , THEWLIS, Kevin, Michael , WARD, Simon, E
发明人： CHAN, Wai, Ngor , HARRISON, Stephen , HUGHES, Owen, Rhys , NEESOM, James, Kenneth , THEWLIS, Kevin, Michael , WARD, Simon, E
IPC分类号： C07D263/48 , C07D417/12 , A61K31/427 , A61P25/00
CPC分类号： C07D277/42 , C07D417/12 , C07D491/052
摘要： The invention provides compounds of formula (I) and salts thereof wherein R1, R2, R3, R4 and X are as defined in the description. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
摘要翻译：本发明提供式（I）化合物及其盐，其中R 1，R 2，R 3，R 4和X如说明书中所定义。还公开了制备方法，药物组合物及其作为药物的用途，例如用于治疗谷氨酸受体功能如精神分裂症或认知障碍的还原或不平衡介导的疾病或病症。

3. 发明申请

WO2003068760A2 COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY 审中-公开
标题翻译：化合物在5HT1型受体中的有益作用及其在治疗中的应用
公开(公告)号：WO2003068760A2
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001709
申请日：2003-02-17
申请人： GLAXO GROUP LIMITED , SMITH, Paul, W , THEWLIS, Kevin, Michael , VONG, Antonio, Kuok, Keong , WARD, Simon, E
发明人： SMITH, Paul, W , THEWLIS, Kevin, Michael , VONG, Antonio, Kuok, Keong , WARD, Simon, E
IPC分类号： C07D295/00
CPC分类号： C07D401/12 , C07D215/20 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (I) wherein: A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; X is carbon, Y is CH and is a double bond; or X is CH, Y is CH2 or oxygen and is a single bond; or X is nitrogen, Y is CH2 and is a single bond; R1 is halogen, hydroxy, cyano, C1-6alkyl, haloC1-6alkyl or C1-6alkoxy; a is 0, 1, 2, 3 or 4; R2 and R3, together with the nitrogen atom to which they are attached, form a nitro group or an optionally substituted 3 to 7 membered heterocyclic group, or R2 and R3 are independently hydrogen, aroyl, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl, arylC1-6alkyl or a group CO(CH2)bNR4R5 wherein b is 1, 2, 3 or 4 and R4 and R5 are independently hydrogen or C1-6alkyl, or R4 and R5, together with the nitrogen atom to they are attached, form part of an optionally substituted 3 to 7 membered heterocyclic group. Methods of preparing the compounds and uses of the compounds in therapy, in particular for CNS disorders such as depression and anxiety, are also disclosed.
摘要翻译：公开了式（I）化合物及其药学上可接受的盐：（I）其中：A为任选取代的苯基，萘基，吲哚基，喹啉基，喹唑啉基，吲唑基，异喹啉基或苯并呋喃基; X是碳，Y是CH并且是双键; 或X是CH，Y是CH 2或氧并且是单键; 或X为氮，Y为CH 2且为单键; R 1是卤素，羟基，氰基，C 1-6烷基，卤代C 1-6烷基或C 1-6烷氧基; a是0，1，2，3或4; R2和R3与它们所连接的氮原子一起形成硝基或任选取代的3至7元杂环基，或者R 2和R 3独立地是氢，芳酰基，C 1-6烷基，C 1-6烷酰基，氟C 1-6烷基， C 1-6烷酰基，C 1-6烷基磺酰基，氟C 1-6烷基磺酰基，氨基甲酰基，C 1-6烷基氨基甲酰基，芳基C 1-6烷基或CO（CH 2）b NR 4 R 5基团，其中b为1,2,3或4，并且R 4和R 5独立地为氢或C 1-6烷基，或 R4和R5与它们连接的氮原子一起形成任选取代的3至7元杂环基的一部分。还公开了制备化合物的方法和化合物在治疗中的用途，特别是CNS障碍如抑郁和焦虑。

4. 发明申请

WO2010066658A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE 审中-公开
标题翻译：可能拮抗AMPA受体的化合物及其在医药中的应用
公开(公告)号：WO2010066658A1
公开(公告)日：2010-06-17
申请号：PCT/EP2009/066476
申请日：2009-12-07
申请人： GLAXO GROUP LIMITED , BRADLEY, Daniel, Marcus , CARDULLO, Francesca , MARSHALL, Howard , MARZORATI, Paola , POZZAN, Alfonso , WARD, Simon, E
发明人： BRADLEY, Daniel, Marcus , CARDULLO, Francesca , MARSHALL, Howard , MARZORATI, Paola , POZZAN, Alfonso , WARD, Simon, E
IPC分类号： C07D207/26 , C07D213/63 , C07D213/74 , C07D231/12 , C07D233/58 , C07D471/04 , C07D495/04 , A61K31/4184 , A61P25/18
CPC分类号： C07D213/63 , C07D207/26 , C07D213/74 , C07D231/12 , C07D233/58 , C07D471/04 , C07D495/04
摘要： A compound of Formula (I) or a salt thereof are provided: wherein R is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
摘要翻译：提供式（I）化合物或其盐：其中R在说明书中定义。还公开了制备方法，药物组合物及其作为药物的用途，例如用于治疗谷氨酸受体功能如精神分裂症或认知障碍的还原或不平衡介导的疾病或病症。

5. 发明申请

WO2010057865A1 N- INDEN- 2 -YL- ISOPROPYLSULFONAMIDES AS AMPA RECEPTOR POTENTIATORS 审中-公开
标题翻译：作为AMPA受体拮抗剂的N-茚-2-基异吲哚磺酰胺
公开(公告)号：WO2010057865A1
公开(公告)日：2010-05-27
申请号：PCT/EP2009/065263
申请日：2009-11-17
申请人： GLAXO GROUP LIMITED , COULTON, Steven , GILPIN, Martin , WARD, Simon, E
发明人： COULTON, Steven , GILPIN, Martin , WARD, Simon, E
IPC分类号： C07C311/07 , A61K31/18 , A61P25/28 , C07D213/643
CPC分类号： C07D213/643 , C07C311/07 , C07C2602/08
摘要： A compound of formula (I) and salts thereof are provided: Wherein n and R 1 are defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
摘要翻译：提供式（I）化合物及其盐：其中n和R1在说明书中定义。还公开了制备方法，药物组合物及其作为药物的用途，例如用于治疗谷氨酸受体功能如精神分裂症或认知障碍的还原或不平衡介导的疾病或病症。

6. 发明申请

WO2003068772A1 HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY 审中-公开
标题翻译：在5HT1型受体上具有重要性的杂环化合物及其在治疗中的应用
公开(公告)号：WO2003068772A1
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001711
申请日：2003-02-17
申请人： GLAXO GROUP LIMITED , HARRINGTON, Frank, Peter , SMITH, Paul, William , WARD, Simon, E
发明人： HARRINGTON, Frank, Peter , SMITH, Paul, William , WARD, Simon, E
IPC分类号： C07D413/12
CPC分类号： C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:(I)wherein A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; b is 1, 2 or 3 and c is 1, 2 or 3, wherein b + c is 2, 3, 4 or 5; X is carbon, Y is CH, is a double bond and e is 0; or X is carbon, Y is CH2 or oxygen, is a single bond and e is 1; or X is nitrogen, Y is CH2, is a single bond and e is 0; R1 is hydrogen, cyano, halogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, NHCOCH3 or OCONR5R6, wherein R5 and R6 are independently hydrogen or C1-6alkyl; R2 is halogen, cyano or C1-6alkoxy; d is 0, 1, 2 or 3; R3 is hydrogen, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl or arylC1-6alkyl; and R4, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring, provided that when a compound of formula (I) has the following structure: wherein A, b, c, R1, e, X, Y, R2 and d are as defined above and R3 is hydrogen, C1-6alkyl or arylC1-6alkyl, then (i) X is carbon, Y is CH and is a double bond; or (ii) b and c are both 1; or (iii) the carbon atom adjacent to the oxo-substituted carbon atom in the morpholinyl ring, marked " * ", is substituted. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
摘要翻译：公开了式（I）化合物及其药学上可接受的盐：（I）其中A是任选取代的苯基，萘基，吲哚基，喹啉基，喹唑啉基，吲唑基，异喹啉基或苯并呋喃基; b为1,2或3，c为1,2或3，其中b + c为2,3,4或5; X是碳，Y是CH，是双键，e是0; 或X为碳，Y为CH 2或氧，为单键，e为1; 或X是氮，Y是CH 2，是单键，e是0; R 1是氢，氰基，卤素，C 1-6烷基，C 1-6烷氧基，C 1-6烷氧基C 1-6烷基，NHCOCH 3或OCONR 5 R 6，其中R 5和R 6独立地是氢或C 1-6烷基; R2是卤素，氰基或C1-6烷氧基; d为0,1,2或3; R 3是氢，C 1-6烷基，C 1-6烷酰基，氟C 1-6烷酰基，C 1-6烷基磺酰基，氟C 1-6烷基磺酰基，氨基甲酰基，C 1-6烷基氨基甲酰基或芳基C 1-6烷基; 并且R 4与其所连接的氮原子一起形成与苯环稠合的任选取代的5至7元杂环基，条件是当式（I）化合物具有以下结构时：其中A，b， c，R1，e，X，Y，R2和d如上定义，R3是氢，C1-6烷基或芳基C1-6烷基，则（i）X是碳，Y是CH并且是双键; 或（ii）b和c均为1; 或（iii）标记为“*”的吗啉基环上与氧代取代的碳原子相邻的碳原子被取代。还公开了制备化合物的方法和化合物在治疗中的用途，特别是用于CNS障碍如抑郁或焦虑的用途。

7. 发明申请

WO2003068236A1 PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS 审中-公开
标题翻译： 5HT-1型受体的磷酸和哌嗪衍生物
公开(公告)号：WO2003068236A1
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001710
申请日：2003-02-17
申请人： GLAXO GROUP LIMITED , FLYNN, Sean, Thomas , SMITH, Paul, W , THEWLIS, Kevin, Michael , WARD, Simon, E , WYMAN, Paul, Adrian
发明人： FLYNN, Sean, Thomas , SMITH, Paul, W , THEWLIS, Kevin, Michael , WARD, Simon, E , WYMAN, Paul, Adrian
IPC分类号： A61K31/495
CPC分类号： C07D401/12 , C07D215/20 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:wherein A is optionally substituted phenyl, indolyl, quinolinyl, quinazolinyl, indazolyl or isoquinolinyl; X is carbon, Y is CH and is a double bond; or X is CH, Y is CH 2 or oxygen and is a single bond; or X is nitrogen, Y is CH 2 and is a single bond; R1 is halogen, cyano, nitro, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 3-7 heterocyclylC 1-6 alkyl, C 3-7 heterocyclyl C 1-6 alkoxy; a is 0, 1, 2, 3 or 4; R2 is either: halogen, -CN, an optionally substituted C 3-7 cycloalkyl, an optionally substituted aryl or an optionally substituted C-linked 3-7 membered heterocyclic group; or a group -(Z)b-B wherein: (i) Z is oxygen, CH 2 , C=O, SO 2 or C=N-OR3 wherein R3 is hydrogen or C 1-6 alkyl; b is 1, 2, or 3; and B is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkanoyl, fluoroC 1-6 alkanoyl, C 1-6 alkylsulfonyl, fluoroC¿ 1-6 alkylsulfonyl, carbamoyl or C 1-6 alkylcarbamoyl, or R4 and R5, together with the nitrogen atom to which they are attached, form part of an optionally substituted 3 to 7 membered heterocyclic group; or (ii) Z is oxygen, CH or CH 2 , b is 1, and B forms the rest of an aryl or a C 3-7 heterocyclic group fused to the phenyl ring; excluding 1-[2-[2-(phenylmethyl)phenoxy]ethyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-piperazine and pharmaceutically acceptable salts thereof, and N-[4-[2-[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]ethoxy]phenyl]-ethanesulfonamide and pharmaceutically acceptable salts thereof. Methods of preparing the compounds and uses of the compounds in therapy, in particular for CNS disorders such as depression and anxiety, are also disclosed.
摘要翻译：公开了式（I）化合物及其药学上可接受的盐：其中A是任选取代的苯基，吲哚基，喹啉基，喹唑啉基，吲唑基或异喹啉基; X是碳，Y是CH并且是双键; 或X是CH，Y是CH 2或氧并且是单键; 或X为氮，Y为CH 2且为单键; R 1是卤素，氰基，硝基，C 1-6烷基，卤代C 1-6烷基，C 1-6烷氧基，C 3-7杂环基C 1-6烷基，C 3-7杂环基C 1-6烷氧基; a是0，1，2，3或4; R 2是：卤素，-CN，任选取代的C 3-7环烷基，任选取代的芳基或任选取代的C-连接的3-7元杂环基; 或（Z）b-B基团，其中：（i）Z是氧，CH 2，C = O，SO 2或C = N-OR 3，其中R 3是氢或C 1-6烷基; b为1,2或3; 并且B是氢，C 1-6烷基，C 3-7环烷基，C 1-6烷氧基或NR 4 R 5，其中R 4和R 5独立地是氢，C 1-6烷基，C 3-7环烷基，C 1-6烷酰基，氟C 1-6烷酰基，C 1 -6烷基磺酰基，氟代C 1-6烷基磺酰基，氨基甲酰基或C 1-6烷基氨基甲酰基，或者R 4和R 5与它们所连接的氮原子一起形成任选取代的3至7元杂环基的一部分; 或（ii）Z是氧，CH或CH 2，b是1，B形成与苯环稠合的芳基或C 3-7杂环基的其余部分; 不包括1- [2- [2-（苯基甲基）苯氧基]乙基] -4 - [（2,3,4-三甲氧基苯基）甲基] - 哌嗪及其药学上可接受的盐，以及N- [4- [2- [4 - [（3,4-二甲氧基苯基）甲基] -1-哌嗪基]乙氧基]苯基] - 乙磺酰胺及其药学上可接受的盐。还公开了制备化合物的方法和化合物在治疗中的用途，特别是CNS障碍如抑郁和焦虑。

8. 发明申请

WO2010037760A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE 审中-公开
标题翻译：潜在的AMPA受体的化合物及其在医学中的应用
公开(公告)号：WO2010037760A1
公开(公告)日：2010-04-08
申请号：PCT/EP2009/062652
申请日：2009-09-30
申请人： GLAXO GROUP LIMITED , WARD, Simon, E , BERTHELEME, Nicolas
发明人： WARD, Simon, E , BERTHELEME, Nicolas
IPC分类号： C07D207/08 , C07D307/12 , A61K31/341 , A61K31/40 , A61P25/00
CPC分类号： C07D307/12 , C07D207/08
摘要： A compound of formula (I) and salts thereof are provided wherein Y is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
摘要翻译：提供式（I）化合物及其盐，其中Y在说明书中定义。还公开了制备方法，药物组合物及其作为药物的用途，例如用于治疗谷氨酸受体功能如精神分裂症或认知障碍的还原或不平衡介导的疾病或病症。

9. 发明申请

WO2003068771A1 HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS 审中-公开
标题翻译： 5HT-1型受体的异环甲基哌啶和磷酸盐
公开(公告)号：WO2003068771A1
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001708
申请日：2003-02-17
申请人： GLAXO GROUP LIMITED , WARD, Simon, E
发明人： WARD, Simon, E
IPC分类号： C07D413/12
CPC分类号： C07D401/12 , C07D215/20 , C07D413/14
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein: A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; X is carbon, Y is CH and === is a double bond; or X is CH, Y is CH 2 or oxygen and === is a single bond; or X is nitrogen, Y is CH 2 And === is a single bond; R1is halogen, cyano, or C 1-6 alkoxy; a is 0, 1, 2 or 3; b is 0 or 1; R2 is hydrogen, C 1-6 alkyl, C 1-6 alkanoyl, fluoroC 1-6 alkanoyl, C 1-6 alkylsulfonyl, fluoroC 1-6 alkylsulfonyl, carbamoyl, C 1-6 alkylcarbamoyl or arylC 1-6 alkyl; and R3, together with the nitrogen atom to which it is attached, forms an optionally substituted 5 to 7 membered heterocyclic group fused to the benzene ring. Methods of preparing the compounds and uses of the compounds in therapy, in particular for a CNS disorder such as depression or anxiety, are also disclosed.
摘要翻译：公开了式（I）化合物及其药学上可接受的盐，其中：A为任选取代的苯基，萘基，吲哚基，喹啉基，喹唑啉基，吲唑基，异喹啉基或苯并呋喃基; X是碳，Y是CH，===是双键; 或X是CH，Y是CH 2或氧，并且= =是单键; 或X为氮，Y为CH2，===为单键; R1为卤素，氰基或C1-6烷氧基; a是0,1,2或3; b为0或1; R 2是氢，C 1-6烷基，C 1-6烷酰基，氟C 1-6烷酰基，C 1-6烷基磺酰基，氟C 1-6烷基磺酰基，氨基甲酰基，C 1-6烷基氨基甲酰基或芳基C 1-6烷基; 并且R 3与连接的氮原子一起形成与苯环稠合的任选取代的5至7元杂环基。还公开了制备化合物的方法和化合物在治疗中的用途，特别是用于CNS障碍如抑郁或焦虑的用途。

10. 发明申请

WO2003068760A3 COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS 审中-公开
公开(公告)号：WO2003068760A3
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001709
申请日：2003-02-17
申请人： GLAXO GROUP LIMITED , SMITH, Paul, W , THEWLIS, Kevin, Michael , VONG, Antonio, Kuok, Keong , WARD, Simon, E
发明人： SMITH, Paul, W , THEWLIS, Kevin, Michael , VONG, Antonio, Kuok, Keong , WARD, Simon, E
IPC分类号： C07D401/12
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (I) wherein: A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; X is carbon, Y is CH and is a double bond; or X is CH, Y is CH2 or oxygen and is a single bond; or X is nitrogen, Y is CH2 and is a single bond; R1 is halogen, hydroxy, cyano, C1-6alkyl, haloC1-6alkyl or C1-6alkoxy; a is 0, 1, 2, 3 or 4; R2 and R3, together with the nitrogen atom to which they are attached, form a nitro group or an optionally substituted 3 to 7 membered heterocyclic group, or R2 and R3 are independently hydrogen, aroyl, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl, arylC1-6alkyl or a group CO(CH2)bNR4R5 wherein b is 1, 2, 3 or 4 and R4 and R5 are independently hydrogen or C1-6alkyl, or R4 and R5, together with the nitrogen atom to they are attached, form part of an optionally substituted 3 to 7 membered heterocyclic group. Methods of preparing the compounds and uses of the compounds in therapy, in particular for CNS disorders such as depression and anxiety, are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式